These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29181962)

  • 1. Unmet needs in children with diabetes: the role of basal insulin.
    Tumini S; Carinci S
    Minerva Pediatr; 2017 Dec; 69(6):513-530. PubMed ID: 29181962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 7. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical contribution of new basal analogue insulin].
    Adamíková A
    Vnitr Lek; 2016; 62(7-8):534-8. PubMed ID: 27627074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.
    Bohn B; Zimmermann A; Wagner C; Merger S; Dunstheimer D; Kopp F; Gollisch K; Zindel V; Holl RW;
    Diabetes Res Clin Pract; 2017 Jul; 129():52-58. PubMed ID: 28505544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
    Philis-Tsimikas A; Zhang Q; Walker C
    Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
    Tibaldi J; Hadley-Brown M; Liebl A; Haldrup S; Sandberg V; Wolden ML; Rodbard HW
    Diabetes Obes Metab; 2019 Apr; 21(4):1001-1009. PubMed ID: 30552800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.